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Sheep red blood cells (SRBCs) have long been used
as a model antigen for eliciting systemic immune re-
sponses, yet the basis for their adjuvant activity has
been unknown. Here, we show that SRBCs failed to
engage the inhibitory mouse SIRPa receptor on
splenic CD4+ dendritic cells (DCs), and this failure
led to DC activation. Removal of the SIRPa ligand,
CD47, from self-RBCs was sufficient to convert them
into an adjuvant for adaptive immune responses. DC
capture of Cd47–/– RBCs and DC activation occurred
within minutes in a Src-family-kinase- and CD18-in-
tegrin-dependent manner. These findings provide an
explanation for the adjuvant mechanism of SRBCs
and reveal that splenic DCs survey blood cells for
missing self-CD47, a process that might contribute
todetecting andmounting immune responsesagainst
pathogen-infected RBCs.
INTRODUCTION
The efficacy of xenogeneic red blood cells in promoting antibody
responses is instrumental in elucidating key aspects of T cell
help of immune responses (Hunter et al., 1974; Jerne andNordin,
1963; Mitchell and Miller, 1968). In more recent years, SRBCs
have been widely used as a simple method to elicit robust
CD4+ T cell and antibody responses and to elucidate require-
ments for germinal center (GC) and memory B cell generation
(Dogan et al., 2009; Kraal et al., 1982; Shinall et al., 2000). Clini-
cally, RBC immunogenicity is an important factor in the induction
of alloantibody responses against minor histocompatibility anti-
gens in 3%–6% of people receiving blood-group-matched RBC
transfusions and a much higher frequency in people receiving
Rhesus-antigen mismatched transfusions (Zimring and Hen-
drickson, 2008). RBC immunogenicity is also likely to be an
important factor in the development of autoimmune hemolytic
anemia. Given that RBCs lack or minimally express major histo-
compatibility complex (MHC) molecules and are infected by
pathogens such as malaria that have had selective influences764 Immunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc.on the human population, it seems likely that specialized im-
mune-sensing systems have evolved that contribute to RBC
immunogenicity. However, despite the long period of study,
the molecular basis for foreign RBC adjuvant activity has re-
mained enigmatic.
The mouse spleen contains two major dendritic cell (DC) sub-
sets, CD4+ and CD8+ DCs, with smaller numbers of double-
negative DCs (Miller et al., 2012). CD4+ DCs are best defined
for their role in promoting CD4+ T cell responses and, in turn,
antibody responses, whereas CD8+ DCs have a role in antigen
cross-presentation to CD8+ T cells (Miller et al., 2012). CD4+
DCs, particularly those identified by co-expression of the lectin
DCIR2, are enriched in regions of the spleen known as marginal
zone (MZ) bridging channels, located between the T zone and
red pulp (Witmer and Steinman, 1984). DC positioning in these
channels is dependent on the chemoattractant receptor EBI2
(GPR183) (Gatto et al., 2013; Yi and Cyster, 2013). A specialized
feature of the spleen is its open circulation; blood is released in
the marginal sinus to then flow through the MZ and on to the
red pulp (Mebius and Kraal, 2005). RBCs travel with this flow
and, after passing through the macrophage-rich MZ and red
pulp, return to circulation via venous sinuses (Mebius and Kraal,
2005). The positioning of CD4+ DCs in the MZ bridging channel
places them in a location that is exposed to RBCs (Yi and Cyster,
2013).
CD47 (also known as integrin-associated protein, IAP) is a cell
surface protein expressed by most cell types, including RBCs
(Barclay and Van den Berg, 2014; Oldenborg, 2013). CD47
engagement of the polymorphic signal regulatory protein a
(SIRPa) on macrophages transmits a ‘‘don’t eat me’’ signal that
prevents cell engulfment. CD47-deficient RBCs, as well as
various other cell types such as cancer stem cells, are rapidly
cleared from circulation in wild-type (WT) mice but not in mice
lacking SIRPa (Chao et al., 2012; Oldenborg, 2013). The SIRPa
negative signal involves immunoreceptor tyrosine-based inhibi-
tory motif (ITIM)-mediated recruitment of protein-tyrosine phos-
phatases (SHP1 and SHP2) that counteract pro-phagocytic
signals (Barclay and Van den Berg, 2014; Oldenborg, 2013).
The pro-phagocytic receptor-ligand systems that trigger phago-
cytosis ofCd47–/– cells are not well defined, but low-density lipo-
protein (LDL)-related protein-1 (LRP1) on macrophages binding
to calreticulin on target cells has been implicated in some situa-
tions (Chao et al., 2010; Gardai et al., 2005). Mice deficient in
Figure 1. Xenogeneic RBCs Activate Splenic CD4+ DCs
(A) Mice were i.v. immunized with SRBC or PBS control and analyzed 3 hr later
by flow cytometry for CD86, MHCII, and CCR7 in gated CD4+ DCs. One
representative flow cytometry pattern is shown (n > 6 animals).
(B) Gene expression in CD4+ DCs from mice immunized with SRBCs 1 hr
earlier relative to CD4+ DCs from PBS (control)-treated mice, determined by
RNA-seq analysis. Average of two replicated experiments is shown. See also
Table S1.
(C) Binding of WT or Cd47/ mouse, sheep, and human RBCs to plate-
bounded Sirpa-Fc. Points indicate mean ± SE (n = 3).The experiment was
independently replicated three times with RBCs from different mice, sheep,
and human donors. See also Figure S1.CD47 or SIRPa have reduced numbers of CD4+ DCs, and this
DC-deficiency has been associated with a reduced ability to
mount antibody responses (Hagnerud et al., 2006; Saito et al.,
2010; Van et al., 2006). However, the basis for the CD4+ DC defi-
ciency in Cd47–/– or Sirpa–/– mice has not been elucidated.
CD47-SIRPa interactions are not well conserved across spe-
cies, and we report here that sheep RBCs failed to bind mouse
SIRPa. We show that SRBCs were strong activators of splenic
CD4+ DCs, and we go on to show that removal of CD47 from
mouse RBCs was sufficient to confer upon them ‘‘SRBC-like’’
immunogenicity. RBC-mediated splenic CD4+ DC activation
occurred extremely rapidly (within minutes) and was then fol-lowed after 2–3 days by a DC depletion that phenocopied the
splenic DC deficiency in Cd47/ and Sirpa–/– mice. Cd47–/–
RBC-mediated DC activation required signaling via Src-family
kinases and was partially dependent on CD18-containing integ-
rins. These data provide an explanation for the adjuvant activity
of foreign RBCs and cells with reduced CD47 expression and
they reveal a role for splenic MZ-bridging-channel DCs in self-
RBC surveillance and in triggering immunity against RBCs.
RESULTS
SRBCs Activate Splenic CD4+ DCs and Promote
Migration to the T Zone
During studies on EBI2-mediated MZ-bridging-channel posi-
tioning of CD4+ DCs, we observed that SRBCs could provoke
DC CCR7 chemokine receptor upregulation and migration to
the T cell zone (Yi and Cyster, 2013). Examining this process in
detail, we found that within 6 hr of SRBC injection, splenic
CD4+ DCsmarkedly upregulated CD86 andMHC class II (MHCII)
as well as CCR7 (Figure 1A). This activation effect required intact
SRBCs because it did not occur after injection of sonicated cells
(Figure S1A). RNAseq analysis showed that 1 hr after SRBC
injection, the DCs increased expression of transcripts for
numerous maturation markers, including costimulatory mole-
cules, lysosomal markers, and a range of cytokines and chemo-
kines (Figure 1B and Table S1). Similar DC activation occurred
after transfer of human RBCs (Figure S1B). Following injection,
many foreign RBCs are captured in the splenic marginal zone
by resident macrophages (Hagnerud et al., 2006; Yi and Cyster,
2013). However, ablation of these macrophages by treating
Cd169-DTR mice with diphtheria toxin (DT) (Miyake et al.,
2007) did not prevent DC activation by SRBCs (Figure S1C).
Immunofluorescence microscopy of spleen tissue taken 15 min
after PKH26-labeled SRBC injection revealed a close associa-
tion between CD11c+ cells and PKH26 labeling in MZ bridging
channels (Figure S1D). The DC activation occurred in mice
lacking activating Fc receptor expression (Fcer1g–/–) (Figure S1E)
and in mice treated with cobra venom factor to deplete comple-
ment C3 (data not shown), ruling out an essential role for pre-ex-
isting (natural) xenoreactive immunoglobulin G (IgG) antibodies
or the complement factor C3. We next considered whether
CD47might be involved. The CD47 receptor, SIRPa, is highly ex-
pressed on splenic CD4+ DCs (Lahoud et al., 2006; Figures S1F
and S1G). SIRPa is polymorphic and known to often bind CD47
in a species-restricted manner (Barclay and Van den Berg, 2014;
Oldenborg, 2013; Subramanian et al., 2006). In vitro adhesion
assays showed that recombinant 129/Sv-derived mouse SIRPa
supported adhesion of WT mouse RBCs, but it failed to support
adhesion of sheep RBCs (Figure 1C) or, as expected (Subrama-
nian et al., 2006), human RBCs (Figure 1C). Taken together,
these data suggest that SRBCs might be causing CD4+ DC acti-
vation as a result of failing to adequately engage the negative
regulatory SIRPa receptor on the DCs.
CD47-Deficient Self-RBCs Activate Splenic CD4+ DCs
We speculated that if a failure to engage the inhibitory SIRPa
receptor was the basis for the SRBC adjuvant effect, then
removing CD47 from mouse RBCs might be sufficient to make
them stimulatory for CD4+ splenic DCs. Consistent with thisImmunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc. 765
Figure 2. Activation and Uptake of CD47-Deficient RBCs by Splenic CD4+ DCs
(A)Mice were immunizedwith 30 ml PKH26-labeledRBCs fromWT orCd47/mice and analyzed 3 hr later by flow cytometry for CD86,MHCII, CCR7, and PKH26
in gated CD4+ DCs.
(B) CD11c-yfp mice were immunized with 30 ml PKH26-labeled RBCs from Cd47/ mice. 20 min after immunization, spleens were vibratome sectioned and
imaged with two-photon microscopy for YFP and PKH26. Scale bar, 20 mm. See also Movie S1.
(C) Fluoresce microscopy detection of PKH26 in flow cytometry sorted CD11c+MHCII+CD4+ DCs from WT mice immunized 30 min earlier with PKH26-labeled
Cd47/ RBCs.
(D) Mice were i.v. immunized with 5 ml PKH26-labeled WT or Cd47/ RBCs, and CD4+ DCs were analyzed 3 hr later by flow cytometry for PKH26 and for CCR7.
CCR7 staining is shown for CD4+ DCs gated on PKH26hi and PKH26lo cells, as in plots on left.
(E) Mice were immunized with 30 ml Cd47/ RBCs, and mean fluorescence intensity (MFI) of the indicated markers on gated CD4 or CD8+ DCs relative to that of
untreated mice was determined at the indicated time points (mean ± SE, n = 3).
(F) Mice were immunized with 30 ml WT or Cd47/ RBCs, and 6 hr later, spleen sections were stained for DCIR2 (33D1, blue) and IgD (brown). F, follicle; T, T cell
zone; RP, red pulp. Scale bar, 100 mm.
(G) C57BL/6 or NODmicewere i.v. immunized with PBS, humanRBCs, andCd47/RBCs, and analyzed 6 hr later by flow cytometry for CCR7 andCD86 in gated
CD4+ DCs. All above experiments have been independently replicated with at least 3–5 animals. See also Figure S2.hypothesis, 3 hr after injection of Cd47–/– RBCs into WT mice,
splenic CD4+ DCs became uniformly CD86+, MHCIIhi, and
CCR7hi (Figure 2A). Injection of Cd47–/– RBCs labeled with the
red fluorescent membrane dye, PKH26, led to labeling of thema-
jority of splenic CD4+ DCs, indicating that they had captured
RBC or RBC-derived molecules (Figure 2A). Two-photon micro-
scopy of vibratome-cut spleens from Itgax-YFP+ mice that had
received PKH26-labeled Cd47/ RBCs 20 min before revealed
PKH26+-material-bearing DCs that were situated in or near MZ
bridging channels (Figure 2B and Movie S1). When splenic766 Immunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc.DCIR2+ DCs were isolated by flow cytometry 30 min after
PKH26-labeled Cd47/ RBC injection and examined by micro-
scopy, many of the DCs were positive for PKH26 labeling
(Figure 2C).
As little as 5 ml of Cd47/ blood was effective in promoting
activation of splenic CD4+ DCs (Figure S2A). When such low
numbers of PKH26-labeled RBCs were injected, only a fraction
of the CD4+ DCs became dye labeled. Gating on the PKH26hi
versus PKH26lo CD4+ DCs showed that the activation occurred
most completely in the cells that had directly captured labeled
RBCs or RBC fragments (Figure 2D), providing evidence that DC
activation depended on physical contact with the Cd47/
RBCs. The efficacy of Cd47/ RBCs in causing DC activation
was not influenced by themethod of RBCpreparation; blood iso-
lated in Alsever’s solution, EDTA, or heparin had similar DC-stim-
ulating activity (Figure S2B). Injection of white blood cells
isolated from 40 ml of Cd47/ blood had no DC-stimulatory
activity, confirming that the activation was RBC mediated (Fig-
ure S2C). Time course analysis showed surface CD86 and
CCR7 upregulation occurring as early as 1.5 hr after Cd47/
RBC injection and peaking after 6–24 hr (Figure 2E). CD8+ DCs
that express intermediate amounts of SIRPa and are sparse in
the MZ showed much less activation and antigen capture (Fig-
ure 2E and Figures S1F, S1G, and S2D). Immunohistochemical
staining of spleen sections showed that Cd47/ RBCs caused
CD4+ DCs (identified by their co-expression of DCIR2) to rapidly
relocate from the MZ bridging channels to the T cell zone,
particularly the border region between the B and T cell zones
(Figure 2F).
The above findings established that CD47 deficiency was suf-
ficient tomakemouseRBCs stimulatory formouseDCs.We then
asked the reciprocal question: is maintenance of the CD47-
SIRPa interaction sufficient to prevent xenogeneic RBCs
from causing DC activation? Previous work has shown that
although human CD47 does not bind well to most strains of
mouse SIRPa, it does bind strongly to the variant of SIRPa
expressed in the non-obese diabetic (NOD) strain (Kwong
et al., 2014; Takenaka et al., 2007). When human RBCs were
transferred to NOD mice, DC activation did not occur,
whereas it was readily observed when the mice received
Cd47/ mouse RBCs (Figure 2G). These findings further sup-
port the conclusion that lack of CD47-SIRPa engagement is
the main mechanism for xenogeneic RBC-mediated activation
of splenic DCs.
Splenic CD4+ DC Deficiency in Cd47–/– Mice As a Result
of Chronic Signaling
We speculated that if DC activation were occurring solely as a
consequence of CD47-deficiency on RBCs, then short-term
treatment with a SIRPa antagonistic antibody should similarly
lead to CD4+ DC activation. Consistent with this model, 6 hr after
injection of a SIRPa function-blocking antibody (Oldenborg et al.,
2000; Oldenborg et al., 2001; Wang et al., 2007), CD4+ DCs, and
to a much lesser extent CD8+ DCs, showed upregulation of
CD86, MHCII, and CCR7 (Figures 3A and S3A), and CD4+ DCs
relocated from MZ bridging channels into the T cell zone
(Figure 3B). Previous work has shown that SIRPa- and CD47-
deficient mice have a selective deficiency in splenic CD4+ DCs
(Hagnerud et al., 2006; Saito et al., 2010; Van et al., 2006; Figures
S3B and S3C), but the basis for this deficiency has been unclear.
We speculated that it might be a consequence of constant
maturation-inducing signaling occurring in DCs as a result of
the lack of an RBC CD47-triggered negative regulatory signal.
Maturation-inducing signals of other types are known to
shorten DC lifespan (De Trez et al., 2005). Flow cytometric anal-
ysis of the DCs remaining inCd47/mice showed that the CD4+
but not CD8+ DCs had reduced SIRPa surface abundance, sug-
gesting that the inhibitory receptor might be internalized in the
absence of ongoing engagement with CD47 (Figure 3C). Impor-tantly, when WT mice were injected with Cd47/ RBCs, after
the initial period of DC activation, the CD4+ DCs became
depleted, as assessed both by flow cytometry (Figure 3D, left
panel) and immunohistochemistry for DCIR2 (Figure 2E). A
similar CD4+ DC depletion occurred 3 days after anti-SIRPa in-
jection (Figure 3D, right panel). If CD4+ DCs in Cd47/ mice
were continually being matured and depleted by endogenous
RBCs, it seemed likely that they would be hypo-responsive to
further stimulation by this pathway. A prior report found that
Cd47/ mice mounted poor antibody responses against
SRBCs, though the defect was attributed to the reduction in
DC number (Hagnerud et al., 2006). We found that the CD4+
DCs remaining in Cd47/ mice were not activated by SRBCs,
whereas they were fully responsive to lipopolysaccharide (LPS)
(Figure 3F).
Cd47–/– Self-RBCs Have Potent Adjuvant Activity
To test whether Cd47–/–mouse RBCs could function as an adju-
vant for CD4+ T cell responses, ovalbumin (OVA) was coupled to
Cd47/ orWTRBCs and injected intomice harboring OVA-spe-
cific OTII CD4+ T cells. Marked proliferation of the OTII CD4+
T cells occurred in the recipients of Cd47/ but not in the recip-
ients of WT OVA-RBCs (Figure 4A). A similar experiment with
OVA-specific OTI CD8+ T cells showed a lesser but still signifi-
cant difference between mice receiving Cd47/ and those
receiving WT OVA-RBCs (Figure 4A). Phenotypic analysis of
the responding CD4+ OTII T cells at day 3 showed that they up-
regulated ICOS, PD1, and CXCR5, markers of follicular helper
T cells (Figures 4B and S4D). When mice were immunized with
OVA-coupled DCIR2 antibody, Cd47/ RBCs again had an
adjuvant effect, indicating that their action was through DC acti-
vation and not solely through promoting capture of RBC-bound
antigen (Figure S4A). No OTII T cell proliferation was observed in
mice treated with Cd47/ RBCs in the absence of OVA (Fig-
ure S4B). In another approach, we tested whether the DC activa-
tion occurring after SIRPa blockade (Figure 2) was sufficient to
augment T cell responses. In mice immunized with OVA-coupled
DCIR2 antibody, SIRPa blockade led to increased proliferation
of OVA-specific T cells (Figure S4C).
We speculated that if the adjuvant activity of SRBCs occurs
by DCs binding these xenogeneic cells but failing to receive a
SIRPa-negative signal, then this pathway should be disrupted
in Cd47/ hosts as a result of SIRPa already being fully disen-
gaged and unable to distinguish SRBCs from endogenous
RBCs. Consistent with this interpretation, OTII T cells showed
80% lower expansion in Cd47/ hosts than in WT hosts in
response to OVA-SRBCs (Figure 4C) and less induction of PD1
and ICOS (Figure S4D). In accordance with this defect, the
Cd47/ hosts failed to mount a GC response to SRBCs, as
examined by flow cytometry (Figure 4D) and immunohistochem-
istry via the GL7 GC marker (Figure 4E). In comparison to
Cd47/ mice, Ebi2/ mice have a similar deficiency in CD4+
DC numbers (Gatto et al., 2013; Yi and Cyster, 2013), but they
are expected to have intact SIRPa function, and they had normal
DC SIRPa expression (Figure S4F); these mice mounted a GC
response of normal magnitude after SRBC immunization (Fig-
ure 4F). Moreover, the Cd47/ mice mounted a normal splenic
GC response to viral-like particles (VLPs) that contain Toll-like
receptor (TLR)-stimulating nucleic acids (Figure 4F). TheseImmunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc. 767
Figure 3. Blockade of Sirpa Activates Splenic CD4+ DCs and Leads to Their Loss
(A) Mice were i.v. injected with anti-Sirpa or control rat IgG2a and analyzed 6 hr later by flow cytometry for CD86, MHCII, and CCR7 in gated CD4 and CD8+ DCs
(n = 3 mice).
(B) Immunochemistry staining of IgD and DCIR2 (33D1) in splenic sections from mice treated as in (A). Scale bar, 100 mm.
(C) Flow cytometric analysis of Sirpa expression in gated CD4+ and CD8+ DCs fromWT or Cd47/mice. Left panel, representative flow cytomtery pattern; right
panel, MFI of Sirpa expression (mean ± SE, n = 3 mice from two experiments).
(D) Mice were i.v. injected with 30 ml Cd47/ RBCs or anti-Sirpa, and numbers of splenic DCs were quantified 3 days later by flow cytometry (mean ± SE, n = 3
mice).
(E) Mice were i.v. injected with Cd47/ RBCs, and spleen sections were stained for IgD and DCIR2 (33D1) at the indicated time points. Scale bar, 100 mm.
(F) WT or Cd47/mice were i.v. injected with PBS, 30 ml PKH26-labeled SRBCs, or 20 mg LPS and then analyzed 3 hr later by flow cytometry for PKH26, CD86,
and CCR7 in gated CD4+ and CD8+ DCs. One representative flow cytometry pattern is shown (n = 6 mice from two experiments). See also Figure S3.observations support the conclusion that SRBCs activate the
mouse immune system by failing to engage SIRPa on DCs.
Self-RBCs Activate CD4+ DCs via Src-Family Kinase
Signaling
Cd47/ mouse RBCs were effective in promoting CD4+ DC
activation in mice lacking Myd88 and Trif, thus excluding a
requirement for TLR receptors in RBC-triggered DC activation
(Figure 5A). Given that SIRPa is generally thought to inhibit
signaling by recruiting protein tyrosine phosphatases (particu-
larly SHP1 in myeloid cells) (Oldenborg, 2013; Oldenborg et al.,
2001), we tested whether Src-family tyrosine kinases (SFKs)
were required for Cd47/ RBC-mediated DC activation. Anal-
ysis of mice lacking individual SFKs Hck, Fgr, or Lyn, all known
to be important in neutrophil and macrophage signaling (Abram
and Lowell, 2009), showed little effect on the DC response (Fig-
ure S5A), but when Hck, Fgr, and Lyn were all removed, DC acti-
vation and repositioning in response to Cd47/ RBCs was768 Immunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc.blocked (Figures 5B and 5C), whereas activation by LPS re-
mained intact (Figure S5B). Hck, Fgr, and Lyn triple-deficient
mice had normal or increased numbers of CD4+ DCs, and they
were positioned comparably to WT cells (Figures 5C and S5C).
Similar DC activation defects were observed in mixed bone
marrow (BM) chimeras, establishing that the SFK requirement
was DC intrinsic (Figure 5D and Figure S5D). As a further test
of the DC SFK requirement, we generated 50:50 mixed SFK-de-
ficient:Zbtb46-DTR BM chimeras and treated them with DT to
ablate the WT DCs and leave only SFK-deficient DCs. Cd47/
RBCs again failed to activate the SFK-deficient DCs (Figure S5E).
Syk often functions downstream of SFKs (Lowell, 2011), and,
consistent with this kinase contributing to DC activation, CCR7
was less completely induced in CD4+ DCs in Syk–/– fetal liver
chimeras that had been injected with Cd47/ RBCs or SRBCs
(Figure S5F). Analysis of downstream signaling revealed rapid
in vivo upregulation of phospho-p38, pS6, pERK, and pCREB
in a SFK-dependent manner in CD4+ DCs after Cd47/ RBC
Figure 4. Adjuvant Effect of CD47-Deficient RBCs in CD4+ T Cell Responses
(A and B) CD45.1+ OTII or OTI splenocytes were labeled with cell trace violet, adoptively transferred to WTmice, and 1 day later mice were immunized with WT or
Cd47/ RBC-OVA conjugate. (A) Two days post-immunization, T cell proliferation was visualized by violet tracer dilution. (B) Three days post-immunization,
frequency of OVA-specific OTII cells, violet tracer dilution, ICOS, and PD1was examined by flow cytometry. Right three panels are gated onOTII T cells. Numbers
on gates indicate mean (±SE) frequencies for three mice.
(C) CD45.1+ OTII splenocytes were labeled with cell trace violet, adoptively transferred to WT or Cd47/ mice, and 1 day later mice were immunized with
SRBC-OVA conjugate. Frequency of OVA-specific OTII cells and violet tracer dilution on OTII cells was examined by flow cytometry 3 days post-immunization
(mean ± SE, n = 3 mice).
(D– F) WT, Cd47/ mice, Ebi2+/, and Ebi2/ mice were immunized with SRBC or VLPs. Eight days after immunization, GC B cells were examined by flow
cytometric analysis and immunochemistry staining. (D) Representative flow cytometric pattern. (E) Representative spleen sections; GCs are marked with black
arrows. (F) Mean (±SE) frequency of IgDloFashiGL7hi GC B cells among total B cells in indicated mice. All experiments above were independently replicated at
least two times with 3–5 mice each time. Scale bar in (E), 100 mm. **p < 0.01, ***p < 0.001 for unpaired Student’s t test. See also Figure S4.injection (Figures 5E and 5F). Phospho-p38 and pERK had
already peaked 5 min after RBC injection, whereas pCREB
reached a maximum at 60 min (Figure 5E).
CD18-Containing Integrins Are Involved in
RBC-Mediated DC Activation
DCexpressawide rangeof receptors capable of activatingSFKs,
though whether any of these molecules bind RBCs is not known
(Sancho and Reis e Sousa, 2012). Many C-type lectin receptors
depend on the ITAM-containing adaptors DAP12 or Fcεr1g for
surface expression and signaling (Lowell, 2011; Sancho and
Reis e Sousa, 2012). Analysis of mice double-deficient for
DAP12 (Tyrobp/) and FcεRIg showed that Cd47/ RBCs
induced DC activation normally (Figure 6A). Some receptors
signal through another partner known as DAP10 (Lanier, 2009),
but mice lacking the Hcst gene that encodes this co-receptoralso activated normally in response to Cd47/ RBCs (data not
shown). Another important group of SFK-activating receptors
are the integrins (Lowell, 2011). The CD18 (Itgb2)-containing in-
tegrins CD11b and CD11c are defining markers of CD4+ DCs
(Steinmanet al., 1997), and thesecells also expresshighamounts
of CD11a (LFA1) (Balkow et al., 2010). We found that Cd47/
RBCs were inefficiently captured by DCIR2+ CD4+ DCs in
Itgb2/ mice, and the integrin-deficient DCs showed minimal
activation (Figure 6B). The spleens of Itgb2/mice are enlarged
due to myeloid hyperplasia in the red pulp (Scharffetter-Kocha-
nek et al., 1998), making it possible that the requirement for
CD18 was indirect. To test for an intrinsic integrin requirement,
we established Itgb2/:WT mixed BM chimeras. In these ani-
mals, the CD18-deficient cells were selectively compromised in
capturing and becoming activated by Cd47/ RBCs (Figures
6C and 6D). As a further method to test the intrinsic role ofImmunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc. 769
Figure 5. CD47-Deficient RBCs Activate Src-Family Kinase Signaling in CD4+ DCs
(A)Myd88/Trif/mice were immunized with WT or Cd47/ RBCs and analyzed 3 hr later by flow cytometry for CD86, MHCII, and CCR7 in gated CD4+ DCs
(n = 2 mice).
(B and C) WT orHck/Fgr/Lyn/mice were immunized with PKH26-labeledWT orCd47/RBCs. (B) Flow cytometric analysis of PKH26, CD86, MHCII, and
CCR7 in gated CD4+ DCs 3 hr after immunization (n = 5 mice from 3 experiments). (C) Immunohistochemical staining of DCIR2 (33D1) and IgD in spleen sections
taken 6 hr after immunization. Scale bar, 100 mm.
(D) WT CD45.1+ mice were lethally irradiated and reconstituted with mixed BM cells (1:1 ratio) from CD45.1+ WT mice and CD45.2+ Hck/Fgr/Lyn/ mice.
Chimeras were immunized with PKH26-labeled WT or Cd47/ RBCs and analyzed 3 hr later by flow cytometry for PKH26, CD86, and CCR7 in gated CD4+ DCs
(n = 4 mice in each group from two experiments).
(E) WTmice were immunizedwithCd47/RBCs, and splenocytes were fixed at the indicated time points and phospho-p38, -S6, -Erk, and -Crebwere examined
in CD4+ DCs by intracellular flow cytometric staining (n = 3 mice).
(F) WT or Hck/Fgr/Lyn/ mice were immunized with WT or Cd47/ RBCs for 5 min before staining, as in (E). One representative of three replicated ex-
periments is shown. See also Figure S5.CD18 in DCs, we generated mixed Itgb2/:Zbtb46-DTR chi-
meras and treated the animals with DT to selectively ablate WT
DCs prior to RBC injection. CD18-deficient DCs again showed
reduced capture of Cd47/ RBCs and less induction of CCR7
(Figure S6A). Tissue sections from these mice revealed that770 Immunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc.CD18-deficient and WT DCs were distributed similarly in control
chimeras that received WT RBCs (Figure S6B), and there was
incomplete relocalization of Itgb2/ DCs to the outer T cell
zone 6 hr after Cd47/ RBC injection (Figure S6B). These find-
ings provide evidence that CD18-containing integrins function
Figure 6. CD18-Integrin Involvement in
RBC-Mediated DC Activation
(A) Tyrobp/Fcer1g/ mice were i.v. immunized
with WT or Cd47/ RBCs and analyzed 3 hr later
by flow cytometry for CD86, MHCII, and CCR7 in
gated CD4+ DCs (n = 4 mice from two experi-
ments).
(B) Itgb2+/+ and Itgb2/ BM chimeras were
immunized with PBS or PKH26-labeled WT or
Cd47/ RBCs. Flow cytometric analysis of
PKH26, CD86, MHCII, and CCR7 in gated DCIR2
(33D1)+ DCs 3 hr after immunization is shown (n = 5
mice in two experiments).
(C and D) WT CD45.1+ mice that had been recon-
stituted with a 1:1 mixture of BM cells from
CD45.1+ WT and CD45.2+ Itgb2/ mice were
immunized with PKH26-labeled WT or Cd47/
RBCs and analyzed 3 hr later. (C) Representative
flow cytometry pattern for PKH26, CD86, and
CCR7 in gated CD4+ DCs. (D) Mean (± SE) of MFI
for the indicated markers (n = 3 mice). One repre-
sentative of three replicated experiments is shown.
See also Figure S6.intrinsically in DCs during activation by CD47-deficient RBCs.
However, some PKH26 acquisition and DC activation was still
observable in each of these conditions, indicating that there are
additional mechanisms of DC-RBC engagement and DC activa-
tion. Although LRP1 has been implicated in macrophage uptake
of Cd47/ apoptotic cells and RBCs by binding surface-
exposed calreticulin (Gardai et al., 2005; Nilsson et al., 2012),
Lrp1/DCs responded normally toCd47/RBCs (Figure S6C).
Finally, we tested the impact of CD18-integrin deficiency on the
ability to mount CD4 T cell responses. When Itgb2/ BM chi-
meras were immunized with OVA-conjugated Cd47/ RBCs,
they mounted a diminished WT OTII T cell proliferative response
compared to the response in control BM chimeras (Figure S6D).Immunity 43, 764–775Taken together, these findings provide ev-
idence that CD18-containing integrins
contribute to the efficiency of DC activa-
tion by Cd47/ self-RBCs.
DISCUSSION
CD47 is a marker of ‘‘self’’ on RBCs, and
cells lacking CD47 are rapidly cleared
from the bloodstream by macrophages
(Oldenborg et al., 2000). Our findings pro-
vide evidence that splenic-bridging-chan-
nel DCs survey RBCs for missing self-
CD47. When CD47 is absent or of a type
unable to engage mouse SIRPa, CD4+
DCs are rapidly alerted and become
competent tostimulateCD4Tcell andanti-
body responses. The concept of immune
cell activation by missing-self recognition
is best established for NK cell activation
by cells with reduced or absentMHC class
I (Lanier, 2005; Medzhitov and Janeway,
2002). NK cells utilize a family of ITIM-con-taining receptors that recognize self-MHC class I to inhibit
signaling via activating receptors. Loss of CD47 fromRBCsmight
act to alert DCs thatRBCsare in an altered state in a similar way to
how loss of MHC class I alerts NK cells that nucleated cells are in
an altered state.MHC class I is downregulated duringmany types
of viral infection and also onmany cancer cells. We speculate that
RBC CD47 becomes reduced or less accessible to SIRPa after
infection by certain RBC-tropic pathogens, leading to DC activa-
tion and immunity.
The inhibitory ‘‘don’t eat me’’ signal transmitted by SIRPa
engagement in macrophages has been well characterized (Bar-
clay and Van den Berg, 2014; Chao et al., 2012; Oldenborg,
2013), but the positive signal that it counteracts has been less, October 20, 2015 ª2015 Elsevier Inc. 771
clear. We identify signaling via SFKs as an important positive
signal in DCs. Our data support a model where, in the healthy
state, RBC CD47 engagement of bridging-channel DC SIRPa
transmits negative signals that override positive SFK signals
from surface receptors, the RBC travels on to the red pulp,
and the DC remains in a quiescent state. However, when CD47
surface amounts or availability are reduced, the positive SFK
signals dominate over SIRPa negative signals, leading to RBC
uptake and DC activation and movement to the T cell zone to
promote cognate T cell and antibody responses. The uptake
step, whether of intact RBC or RBC fragments, is likely to involve
tyrosine phosphorylation of several cytoskeletal proteins, as
observed during in vitro studies of IgG-opsonized SRBC phago-
cytosis by human macrophages (Tsai and Discher, 2008).
The factors influencing CD47 abundance on RBCs are not fully
understood, but the amounts reduce gradually as the cells age
(Oldenborg, 2013) and after periods of in vitro storage (Gilson
et al., 2009; Stewart et al., 2005). CD47 in human RBCs exists
in the membrane as a multiprotein complex (Oldenborg, 2013).
Loss of some members of this complex, such as the Rh antigen
or band 3, leads to reduced CD47 expression (Oldenborg, 2013).
The membrane mobility and clustering of CD47 is also affected
when components of the complex are missing (Oldenborg,
2013) and when membrane lipid composition changes (Lv
et al., 2015). In mice, we found that Cd47+/– RBCs failed to stim-
ulate DCs in WT recipients (data not shown), indicating that
CD47 surface density might need to fall more than 50% to cause
DC activation. However, CD47 in mouse RBCs is not in the same
type of complex as human RBCs, making direct comparisons of
mouse and human RBCs difficult (Oldenborg, 2013). In future
studies, it might be possible to take advantage of our finding
that NODSIRPa adequately interacts with human CD47 to inhibit
DC activation to test whether treatments, mutations, or infec-
tions that affect human CD47 abundance or distribution in the
membrane diminish SIRPa engagement to an extent that leads
to DC activation. Such studies might help discern whether this
DC activation pathway contributes to the high frequency of auto-
immune hemolytic anemia in Rh– individuals (Oldenborg, 2013)
and to the immunogenicity of stored allo-RBCs (Gilson et al.,
2009; Hendrickson et al., 2010).
We suggest that positioning in MZ bridging channels allows
CD4+ DCs to survey a large number of passing self-RBCs for
altered or missing self-CD47 expression. White blood cells
(WBCs) are also likely being surveyed in the same way, but given
that RBCs outnumber WBCs by about 1,000 to 1, a major pur-
pose of DC positioning in the bridging channels might be for
exposure to the non-migratory RBCs. RBC engagement of
DCs is likely to occur under fluid shear stress, providing forces
that promote integrin-mediated adhesion and signaling (Woolf
et al., 2007). Although RBCs express little if any of the CD18 in-
tegrin ligands ICAM1 or ICAM2, human and mouse RBCs ex-
press ICAM4 (Bailly et al., 1994; Bailly et al., 1995; Lee et al.,
2006; Lee et al., 2003). In vitro studies have shown that human
ICAM4 can bind all three CD18-containing integrins (Cartron
and Elion, 2008; Ihanus et al., 2007; Lee et al., 2003). However,
by using previously established Icam4/ mice (Lee et al.,
2006), we found that Icam4/ Cd47/ RBCs were captured
by and activated DCs equivalently to Icam4+/+ Cd47/ cells
(data not shown), suggesting that RBCs display additional li-772 Immunity 43, 764–775, October 20, 2015 ª2015 Elsevier Inc.gands for CD18-containing integrins. Alternatively, it is possible
that CD18-containing integrins are acting in an indirect way to
augment DC access to RBCs. Although we did not observe
major alterations in DC positioning in the spleens of DT-treated
Itgb2/ versusWT Zbtb46-DTRmixed BMchimeras, we cannot
exclude the possibility that there are local cell-positioning or cell-
cell interaction differences that affect the extent of exposure to
rapidly moving blood cells. Additionally, given that we did detect
measurable binding ofCd47/ RBCs to Itgb2/ DCs, there are
likely to be further SFK-activating receptors on CD4+ DCs that
have ligands on RBCs. Pro-phagocytic signaling during CD47-
deficient cell binding by macrophages involves LRP1 engage-
ment of surface-exposed calreticulin on target cells (Chao
et al., 2010; Gardai et al., 2005). CD4+ DCs express only low
amounts of LRP1 (Subramanian et al., 2014), and this receptor
did not contribute to DC activation by RBCs. However, it remains
plausible that other calreticulin receptors exist on DCs,
and these could work together with integrins to promote DC
activation.
Uptake of cancer cells by macrophages after CD47 blockade
leads to antigen presentation and stimulation of CD8+ but not
CD4+ T cell responses (Tseng et al., 2013). In that work, CD47-
blocked target cells failed to activate DCs in vitro to a state
with CD4+ T cell stimulatory properties (Tseng et al., 2013).
Consistent with those observations, we were unable to observe
activation of splenic DCs in vitro by SRBCs or Cd47/ RBCs
(data not shown). This could be a consequence of the back-
ground extent of DC maturation that occurs when splenic DCs
are isolated and incubated in vitro, but it might also reflect a
need for features of the in vivo environment, such as exposure
to shear forces, that are not mimicked in the culture system.
However, in vitro studies of human blood-derived DCs have re-
vealed an ability of SIRPa engagement by CD47-Fc or RBCs to
diminish DC activation (Latour et al., 2001; Scha¨kel et al.,
2006). The basis for this discrepancy between mouse and hu-
man in vitro studies is unclear, but these data do suggest that
our in vivo observations will translate to humans.
The basis for the CD4+ DC-deficiency in CD47- and SIRPa-de-
ficient mice has been unclear (Hagnerud et al., 2006; Saito et al.,
2010; Van et al., 2006), though one study provided evidence that
engagement of DC SIRPa by CD47 on both hematopoietic and
stromal cells is involved (Saito et al., 2010). By showing that
blockade of SIRPa or transient treatment with Cd47–/– RBCs is
sufficient to cause a similar deficiency of splenic CD4+ DCs after
3 days as full CD47- or SIRPa-deficiency, we provide support for
a model in which unrestrained RBC-mediated transmission of
activation signals causes sustained DC depletion. This model
is consistent with the observation that SIRPa-deficient CD4+
DCs turn over at an accelerated rate (Saito et al., 2010).We spec-
ulate that RBC-triggered maturation of DCs is followed by their
loss due to apoptosis as has been observed after splenic DC
exposure to LPS (De Trez et al., 2005). We do not exclude the
possibility that CD47 on additional cell types contributes to
maintaining DC quiescence (Saito et al., 2010; Wang et al.,
2007). CD47 and SIRPa-deficient mice have DC reductions in
lymph nodes (LNs), the epidermis, and lamina propria, as well
as in the spleen (Saito et al., 2010; Scott et al., 2014; Washio
et al., 2015). Given that DCs in non-splenic locations might not
be regularly exposed to RBCs, these deficiencies might indicate
that DC interactions with other CD47+ cell types are important,
but it is also possible that other functions of SIRPa and CD47
are needed in different DC types (Barclay and Van den Berg,
2014).
Finally, our demonstration that CD47-deficient RBCs can
serve as adjuvants for CD4+ T cell and antibody responses
adds to recent literature highlighting CD47 antagonism as an
approach to augment macrophage responses against cancer
cells and parasite infected RBCs (Banerjee et al., 2015; Chao
et al., 2012; Tseng et al., 2013). Induction of CD4+ T cell and
antibody responses during CD47-blockade treatments might
contribute to anti-tumor and anti-pathogen effects. Such ap-
proaches could also be valuable in the design of vaccines for
promoting immune responses against malaria and other RBC-
tropic pathogens.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6NCr and C57BL/6-cBrd/cBrd/Cr (CD45.1) mice at the ages of
7–9 weeks were purchased from the National Cancer Institute. NOD mice
were from an internal University of California, San Francisco (UCSF) colony
and were provided by Qizhi Tang. OVA-specific OTII or OTI TCR-transgenic
mice and Cd47/ and Cd18/ mice were purchased from the Jackson
Laboratory. Ebi2/, Lyn/, Fgr/, Hck/Myd88/Trif/, Fcer1g/,
Fcer1g/Tyrobp/, Hcst/, Lyn/Fgr/Hck/, and Syk/ mice were
previously established (Bakker et al., 2000; Lowell et al., 1994; Meng and Low-
ell, 1997; Pereira et al., 2009; Takai et al., 1994; Turner et al., 1995; Yamamoto
et al., 2003) and have been backcrossed onto the C57BL/6 background for at
least ten generations. CD169DTR mice (Miyake et al., 2007) were kindly
provided by Masato Tanaka (RIKEN Research Center for Allergy and Immu-
nology). Zbtb46-DTR mice (Meredith et al., 2012) were from the Jackson Lab-
oratory. BM from Lrp1flox/flox CD11ccre/+ mice (Subramanian et al., 2014) was
provided by Ira Tabas (Columbia University). For BM or fetal liver chimeras,
mice were lethally irradiated by exposure to 1,300 rads of g-irradiation in
two doses 3 hr apart, and BM cells or fetal liver cells (2 3 106 to 5 3 106)
were transferred through the tail vein. Chimeric mice were in most cases
analyzed 6–10 weeks after reconstitution. Diphtheria toxin (DT) (EMD Biosci-
ences) was intraperitoneally injected in 1 mg doses at days 4 and 1 or as
indicated, and the mice received RBCs at day 0. Animals were housed in a
specific pathogen-free environment in the Laboratory Animal Research Center
at UCSF, and all experiments conformed to ethical principles and guidelines
approved by the Institutional Animal Care and Use Committee.
Virus-like Particles and LPS Immunization
Generation and packaging of virus-like particles (VLPs) containing bacterio-
phage Qb antigens and CpG ODN G10 were described in detail previously
(Jegerlehner et al., 2007). For mouse immunization and induction of GCs,
mice were injected intraperitoneally with 50 mg VLPs-CpG. LPS (TLR grade)
was obtained from Axxora, and mice were intravenously (i.v.) injected with
20 mg LPS.
Immunohistochemical Staining and Two-Photon Imaging
Cryosections of 7 mm were fixed and stained immunohistochemically as pre-
viously described (Allen et al., 2004) with the following antibodies: PE-conju-
gated anti-IgD (11-26c.2a, BioLegend), biotin-conjugated anti-GL7 (GL7,
BioLegend), and FITC-conjugated 33D1 (33D1, BioLegend). Images were
captured with a Zeiss AxioOberver Z1 inverted microscope. For multiphoton
imaging, CD11cYFP mice were injected with PKH26-labeled (Sigma-Aldrich)
Cd47/ RBCs 20 min before the spleen was harvested and sectioned longi-
tudinally with a vibratome (Leica). The cut spleen was perfused with
RPMI1640 medium (Life Technologies) plus 10 mM HEPES and 95% CO2
and 5% O2. The cut spleen was imaged with a 7MP two-photon microscope
(Carl Zeiss) equipped with a Chameleon laser (Coherent). Excitation wave-
lengths were 940 nm for YFP and 800 nm for PKH26. The z stack was21 mm thick with 3 mm intervals. The image was acquired with ZEN2012
(Carl Zeiss), and the three dimensional movie was made with Imaris
7.4.2 364 (Bitplane).
CD47-Sirpa Adhesion Assay
A modified version of a previously reported assay was used (Subramanian
et al., 2006). In brief, recombinant 129/Sv strain mouse Sirpa-Fc chimera pro-
tein (sequence ID P97797, R&D Systems) was coated on high-binding ELISA
plates in serial dilutions. 129/Sv SIRPa is 96% identical to C57Bl/6 SIRPa,
and the proteins have similar CD47 binding characteristics (Kwong et al.,
2014; Takenaka et al., 2007). After overnight incubation at 4C, plates were
washed with PBS and blocked with Hanks Balanced Salt solution (HBSS)
buffer containing 1% fatty-acid-free BSA at 37C for 2 hr. After blockade,
plates were washed twice, 50 ml RBCs (1 3 105/ml) diluted in HBSS with 1%
BSA were added, and then the plates were incubated in a 37C cell incubator
for 1 hr. After incubation, non-adhered cells were washed away gently with
PBS six times. Subsequently, 50 ml water was added to the wells for 30 min
to completely lyse the adhered cells. RBCs have pseudoperoxidase activity
of hemoglobin, and the relative numbers of RBCs were quantified by adding
TMB peroxidase (HRP) substrate (Vector Laboratories) to RBC-water solution
for 2–5 min. 25 ml stop solution (2M sulfuric acid) was then used to stop the
reaction, and the plate was read at 450 nM with 540 nm as the correction
wavelength. The dosage curve was calculated with a 4-parameter curve fit.
An additional experiment was performed with a biotinylated fusion protein of
C57BL/6 Sirpa domain 1 and rat CD4 domains 3 and 4 (Kwong et al., 2014),
and this behaved similarly to the 129/Sv strain Sirpa-Fc in showing minimal
binding of SRBC while supporting strong binding of WT mouse RBC.
RNA-Seq Analysis
Flow cytometric sorted DCs (1.0 3 10e6) were snap frozen in liquid nitrogen
and stored at 80C, and RNA was extracted with the QIAGEN RNeasy Kit.
RNA quality was checked with the Agilent 2100 Bioanalyzer (RNA integrity
number > 9 for all samples). Barcoded sequencing libraries were then gener-
ated with 100 ng of RNA with the Ovation RNA-Seq System V2 and Encore
Rapid Library System. The UCSF Human Genetics Core performed next-gen-
eration sequencing (Illumina HiSeq 2500) with 100-bp paired-end reads. Se-
quences were reported as FASTQ files, which were aligned to the mm9mouse
genome with STAR (Spliced Transcript Alignment to a Reference). Generation
of Log2FC values and further analyses were performed with a Bioconductor
package on RStudio.
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